Find your next paid study

University of Michigan Rogel Cancer CenterNCT07645391

~$10 – $750

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help resea…

Breast CarcinomaEsophageal CarcinomaGenitourinary System Carcinoma+6 more

M.D. Anderson Cancer CenterNCT00991094

~$10 – $750

Observational

MATCHES-Novel: MAking Telehealth Delivery of Cancer Care at Home Effective and Safe for Novel Therapies: A Hospital-at-Home Model for Tarlatamab Delivery

The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab…

Small-cell Lung CancerSmall Cell Lung Carcinoma

Memorial Sloan Kettering Cancer CenterNCT06957314

Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamic…

Context Therapeutics Inc.NCT06756035

~$10 – $8,750

Observational

A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors

This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation ther…

Lung CarcinomaLung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the Lung+3 more

Northwestern UniversityNCT05802186

Solid Tumor, AdultColorectal CancerPancreatic Ductal Adenocarcinoma

A Phase 1/2 First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients With Advanced Solid Tumors

This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and…

Crossignal Therapeutics, Inc.NCT06598007

~$10 – $8,750

Observational

Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial

The goal of this clinical trial is to improve the surgical treatment of patients with oral cancer. We will explore whether the use of surgeon performed ultraso…

Tongue CancerOral CancerSquamous Cell Carcinoma of the Oral Cavity or Oropharynx

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more

~$10 – $7,500

Tobias TodsenNCT07203911

Phase 2

Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer

This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative …

Emory UniversityNCT05741164

Phase 2

A Phase II Study of Pembrolizumab in Combination With Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial (Squamous Cell Carcinoma of Head and Neck Response-Guided Therapy)

By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemo…

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck Neoplasms+2 more

University of ChicagoNCT05420948

Solid TumorAdvanced CancerMetastatic Cancer+7 more

Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tol…

~$10 – $8,750

Memgen, Inc.NCT05076760

Metastatic Pancreatic Ductal Adenocarcinoma

Phase I/II Clinical Trial of ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells

The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic d…

Washington University School of MedicineNCT06904378

Phase 2

Optimizing Treatment and Advanced Multi-Imaging Response Evaluation for Very-High-Risk Prostate Cancer (OPTIMAL) - a Phase II Single Arm Study

This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate c…

Prostate Adenocarcinoma